Key result
High-dose cyclophosphamide and adriamycin halts trial due to toxicity without improving efficacy in metastatic sarcomas.
Why the study?
The efficacy and toxicity of intensive chemotherapy with high-dose cyclophosphamide and adriamycin with DTIC maintenance in metastatic soft tissue sarcomas were unclear.
Does intensive chemotherapy with high-dose cyclophosphamide and adriamycin with DTIC maintenance improve response rates in patients with metastatic soft tissue sarcomas?
Does intensive chemotherapy with high-dose cyclophosphamide and adriamycin with DTIC maintenance improve response rates in patients with metastatic soft tissue sarcomas?
High-dose cyclophosphamide and adriamycin with DTIC maintenance yielded a 25% partial response rate with substantial toxicity, leading to early trial termination.
Toxicity without efficacy precludes routine use of this regimen in metastatic STS; leaves open safer, more effective alternatives for trials.
Intensive chemotherapy with high-dose cyclophosphamide and adriamycin with DTIC maintenance was given to 12 patients with metastatic soft tissue sarcomas. A partial response rate of 25% was seen; this is no better than can be achieved with single-agent therapy. Because of substantial toxicity without improved efficacy, the trial of high dose therapy was halted.
No takes yet. Share an insight, caveat, or question.
Clamon et al. (1983) studied this question. High-dose cyclophosphamide and adriamycin with DTIC maintenance yielded a 25% partial response rate in metastatic soft tissue sarcomas, halting the trial due to toxicity without improved efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: